Key Takeaways
Perrigo Company plc's fiscal year 2025 (calendar year ended December 31, 2025) was a year of strategic stabilization following multiple years of operational distress: revenue of approximately $4.05B (essentially flat YoY), adjusted EBITDA of approximately $625-680M at approximately 15-17% margins, and adjusted EPS of approximately $2.40-2.85 reflecting the financial profile of a self-care consumer healthcare company that has spent the past four years digesting two major strategic missteps (the disastrous Nestlé infant formula acquisition completed in FY2022 that was followed by the Abbott infant formula recall crisis, and the broader strategic confusion about whether Perrigo should be a generic pharmaceuticals company, a private-label OTC company, or a branded consumer self-care company). CEO Patrick Lockwood-Taylor, who joined in 2023 from Procter & Gamble after a long career in branded consumer healthcare, has refocused Perrigo on the Consumer Self-Care strategy: divesting non-core generic pharmaceutical assets, exiting unprofitable categories (the Mexican OTC business was sold; the European generics business was carved out), and concentrating capital and management attention on the two remaining core segments — Consumer Self-Care Americas (CSCA, ~63% of revenue) and Consumer Self-Care International (CSCI, ~37% of revenue) — that constitute Perrigo's structural identity as the world's largest store-brand and private-label OTC manufacturer. The investment thesis for Perrigo in FY2026 is fundamentally a debt deleveraging and margin recovery story: gross debt of approximately $4.0-4.5B (down from peak ~$5.5B post-Nestlé acquisition) at approximately 6.5-7.0x adjusted EBITDA needs to be reduced to below 4.0x for the equity to deserve a re-rating, and the operational lift required to achieve that — through a combination of EBITDA recovery (margin restoration in CSCA after the infant formula crisis, productivity gains in CSCI, exit of low-margin SKUs) and absolute debt reduction from FCF — defines the multi-year management agenda. The bull case is that Perrigo's fundamental position as the dominant private-label OTC supplier (selling to Walmart, CVS, Walgreens, Kroger, Costco store brands across pain relief, cough/cold, antacids, allergy, and other categories) is durable and regaining its pre-crisis profitability; the bear case is that private-label OTC is structurally challenged by branded consumer healthcare margin pressure that limits the price increases Perrigo can pass to retailers.
Perrigo was founded in 1887 as a pharmaceutical packaging company in Allegan, Michigan, evolving over decades into the leading private-label OTC manufacturer in the United States. The company's domicile shifted to Ireland in 2013 through the inversion-style merger with Elan Corporation — a tax-driven structural decision that has subsequently generated significant tax controversy with Irish tax authorities (the €1.6B Irish tax dispute, which Perrigo continues to contest, has been a multi-year overhang). Strategic missteps under prior management included the failed $26B unsolicited takeover bid by Mylan in 2015 (which Perrigo successfully resisted but at the cost of significant operational distraction), the divestiture of generic prescription pharmaceuticals to Altaris Capital in 2021 (intended to focus on consumer self-care, but at sale prices that significantly disappointed shareholders), and the catastrophic $4.9B acquisition of Nestlé's US infant formula business in February 2022 — completed just months before the Abbott infant formula recall crisis temporarily sent infant formula category economics into chaos and exposed Perrigo to acute supply chain and regulatory pressure on its newly acquired GoodStart and Nestlé Good Start brands. The recovery of CEO Patrick Lockwood-Taylor (formerly P&G's Vice Chairman of Beauty) and CFO Eduardo Bezerra has focused on simplifying the portfolio, restoring margins, and demonstrating that Perrigo's core private-label OTC business — which remains the largest of its kind globally — can generate durable, capital-light free cash flow once the infant formula and corporate overhead noise is normalized.
Business Structure
Perrigo reports through two segments after the divestiture of non-core generic and prescription assets.
Consumer Self-Care Americas / CSCA (~63% of revenue, ~$2.55B FY2025): CSCA manufactures and markets store-brand and private-label OTC products in the US, Canada, and Mexico (Mexico business divested late FY2024). Categories include pain relief (private-label ibuprofen, acetaminophen, naproxen — the largest single category), cough and cold remedies (private-label Mucinex equivalents, expectorants, decongestants), digestive health (antacids, anti-diarrheals, laxatives), women's health (vaginal moisturizers, fertility tests), oral care (toothpastes, mouthwashes), and infant formula (the Nestlé-acquired GoodStart and Nestlé Good Start brands plus existing Perrigo store-brand infant formula). Customers are large US retailers — Walmart, CVS, Walgreens, Kroger, Costco, Target, Albertsons — that contract with Perrigo to manufacture private-label equivalents to branded OTC products. Pricing is contracted at significant discounts to branded equivalents (typically 30-50% lower retail price), with Perrigo's manufacturing scale and category expertise providing operational efficiency that supports its margin model.
Consumer Self-Care International / CSCI (~37% of revenue, ~$1.50B FY2025): CSCI operates branded and private-label consumer healthcare across Europe, with significant presence in UK, Belgium (where Perrigo's branded portfolio is anchored), France, Germany, and Nordics. Brands include ACO (Nordic skincare), Compeed (blister/foot care), Solpadeine (pain relief), and others. The European market structure differs from the US: branded OTC dominates retailer offerings (private-label penetration is lower in EU pharmacy channels), and Perrigo competes with Sanofi, GlaxoSmithKline, Bayer, and Reckitt as a smaller branded-plus-private-label player. CSCI has historically generated higher gross margins than CSCA but lower revenue scale and growth.
Key Core Metrics Performance
Revenue, Margin, and Debt Trajectory (FY2021–FY2025)
| Fiscal Year | Revenue | Adj. EBITDA | Adj. EBITDA Margin | Adj. EPS | Net Debt | Net Debt/EBITDA |
|---|---|---|---|---|---|---|
| FY2021 | ~$4.13B | ~$770M | ~18.6% | ~$2.55 | ~$2.7B | ~3.5x |
| FY2022 | ~$4.45B (post-Nestlé) | ~$685M | ~15.4% | ~$1.95 | ~$5.3B | ~7.7x |
| FY2023 | ~$4.66B | ~$575M | ~12.3% | ~$1.55 | ~$5.1B | ~8.9x |
| FY2024 | ~$4.20B (post-divestitures) | ~$615M | ~14.6% | ~$2.10 | ~$4.6B | ~7.5x |
| FY2025 | ~$4.05B | ~$650M | ~16.0% | ~$2.65 | ~$4.1B | ~6.3x |
The margin trough in FY2023 — when adjusted EBITDA margin fell to ~12.3% — reflects the accumulation of operational pressures: infant formula category cost inflation, pricing concessions to retailers during the supply chain crisis, integration challenges from the Nestlé acquisition, and the European business margin compression from elevated raw material costs. The recovery toward 16% by FY2025 reflects pricing actions taken through CSCA contract renegotiation cycles, productivity programs, and the deliberate divestiture of the lowest-margin business lines.
Segment Margin Analysis (FY2025)
| Segment | Revenue | Adj. Operating Margin | Adj. Op. Income |
|---|---|---|---|
| CSCA | ~$2.55B | ~13-15% | ~$340-385M |
| CSCI | ~$1.50B | ~14-16% | ~$210-240M |
| Corporate / Other | — | — | ~-$95M |
| Total | ~$4.05B | ~13-14% | ~$455-530M |
CSCA's margin recovery has been faster than CSCI's, partly because the infant formula business reaches normalized operating economics 2-3 years after the supply chain crisis abated, and partly because the FY2024 Mexican business divestiture removed a structurally low-margin asset.
Debt Reduction Plan
| Year | Gross Debt | Cash | Net Debt | Annual FCF | Debt Repayment |
|---|---|---|---|---|---|
| FY2022 | ~$5.7B | ~$0.4B | ~$5.3B | ~$200M | — |
| FY2023 | ~$5.6B | ~$0.5B | ~$5.1B | ~$245M | ~$100M |
| FY2024 | ~$5.0B | ~$0.4B | ~$4.6B | ~$310M | ~$600M |
| FY2025 | ~$4.5B | ~$0.4B | ~$4.1B | ~$340M | ~$500M |
Annual debt repayment of approximately $500-600M reflects the disciplined capital allocation toward leverage reduction — the management team has communicated that no significant capital returns (buybacks beyond modest amounts) will be pursued until net leverage falls below 4.0x adjusted EBITDA.
Market Evaluation
Perrigo trades at approximately 8-12x forward adjusted EPS and approximately 6-8x forward adjusted EBITDA — a discount to consumer healthcare peers (Haleon, Kenvue at 12-16x EBITDA) that reflects both the leverage and the questions about durable margin profile. The bull case is leverage normalization: if EBITDA recovers to $700-750M by FY2027 and net debt declines to $3.0-3.2B, net leverage falls to ~4.0x — supporting either a re-rating to 9-10x EBITDA or initiation of capital returns that drive equity value. At ~$700M EBITDA and 9x, the equity value implies meaningful upside from current depressed levels. The bear case is structural margin pressure: private-label OTC margins are inherently below branded peer margins, retailer concentration (Walmart, CVS, Walgreens) limits pricing power, and competitive private-label entrants (other contract manufacturers) can pressure share at contract renewal cycles. If EBITDA stalls at ~$625-650M, deleveraging takes 5+ years, and the equity remains range-bound at depressed multiples.
The Private-Label OTC Moat and Retailer Relationships
Perrigo's structural advantage in private-label OTC manufacturing is the combination of regulatory expertise (FDA OTC monograph compliance, manufacturing site approvals), category breadth (ability to offer a retailer a complete private-label OTC portfolio across 100+ SKUs in pain, cough/cold, allergy, digestive, and other categories), and manufacturing scale (Perrigo's plants in Michigan, Tennessee, and elsewhere produce billions of units annually with cost-per-unit economics that smaller contract manufacturers cannot match). For a retailer like Walmart that wants to offer Equate-branded equivalents to every major OTC brand, Perrigo is functionally the only supplier capable of providing the full breadth at consistent quality and supply reliability — switching to multiple smaller suppliers would create supply chain complexity that retailers consciously avoid.
The relationship structure with major retailers involves multi-year contracts (typically 3-5 years) with negotiated pricing schedules, volume commitments, and exclusivity provisions for specific SKU equivalents. The contract renewal cycle is the primary pricing event for Perrigo: as branded OTC pricing has increased meaningfully in 2023-2025 (reflecting consumer healthcare brand pricing power), Perrigo's contract renewals have allowed margin recovery as private-label price points adjust upward proportionally — supporting the gradual EBITDA margin restoration visible in the FY2024-FY2025 trajectory. The risk is that the relationship is asymmetric: each major retailer represents a meaningful share of Perrigo's revenue, while Perrigo represents a small share of any retailer's total OTC purchasing — giving retailers structural negotiating advantage at contract renewal.